Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 22.21 10.66% 2.14
ORIC closed down 4.52 percent on Friday, July 31, 2020, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical ORIC trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 10.66%
NR7 Range Contraction 10.66%
New 52 Week Low Weakness 10.66%
Multiple of Ten Bullish Other 10.66%
Wide Bands Range Expansion 10.66%
Down 3 Days in a Row Weakness 10.66%
Oversold Stochastic Weakness 10.66%
New 52 Week Closing Low Bearish 5.66%
Doji - Bullish? Reversal 5.66%
New 52 Week Low Weakness 5.66%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Health Cancer Clinical Medicine Oncology Treatment Of Cancer Immunotherapy Solid Tumors Cancers Cancer Treatments Chemotherapy Occupational Safety And Health Antineoplastic Drugs Specialty Drugs Cancer Therapeutics Treatment Of Cancers

Is ORIC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 40.67
52 Week Low 19.85
Average Volume 210,984
200-Day Moving Average 0.00
50-Day Moving Average 29.54
20-Day Moving Average 24.00
10-Day Moving Average 23.26
Average True Range 2.59
ADX 20.81
+DI 14.32
-DI 23.52
Chandelier Exit (Long, 3 ATRs ) 26.25
Chandelier Exit (Short, 3 ATRs ) 27.63
Upper Bollinger Band 28.15
Lower Bollinger Band 19.84
Percent B (%b) 0.03
BandWidth 34.65
MACD Line -2.47
MACD Signal Line -2.25
MACD Histogram -0.2204
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.28
Resistance 3 (R3) 22.45 21.88 21.91
Resistance 2 (R2) 21.88 21.32 21.80 21.78
Resistance 1 (R1) 20.98 20.97 20.70 20.81 21.66
Pivot Point 20.41 20.41 20.27 20.33 20.41
Support 1 (S1) 19.51 19.85 19.23 19.34 18.48
Support 2 (S2) 18.94 19.50 18.86 18.36
Support 3 (S3) 18.04 18.94 18.23
Support 4 (S4) 17.87